- Jun 10, 2021
NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM
NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...
204
- Jun 10, 2021
NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dex in TIE NDMM
SABLe NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients...
140
- Jun 9, 2021
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...
647
- Jun 9, 2021
NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM
NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Investigation of...
120
- Jun 9, 2021
NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION
NUTRIVENTION Study NCT04920084: A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or...
465
- Jun 6, 2021
NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...
471